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TT virus (TTV) is a recently identified widespread DNA virus of humans that produces persistent viremia
in the absence of overt clinical manifestations. In an attempt to shed light on the dynamics of chronic infection,
we measured the levels of TTV in the plasma of 25 persistently infected patients during the first 3 months of
alpha interferon (IFN-) treatment for concomitant hepatitis C virus (HCV) infection. The first significant
decline of TTV loads was observed at day 3 versus day 1 for HCV. Subsequently, the loads of TTV became
progressively lower in most patients, but some initial responders relapsed before the end of the follow-up,
suggesting that at least in some subjects the effects of IFN on TTV can be very short-lived. No correlation
between the responses of TTV and HCV to therapy was found. Fitting the viremia data obtained during the first
week of treatment into previously developed mathematical models showed that TTV sustains very active
chronic infections, with over 90% of the virions in plasma cleared and replenished daily and a minimum of
approximately 3.8  1010 virions generated per day. Low levels of TTV were occasionally detected in the
peripheral blood mononuclear cells of patients who had cleared plasma viremia, thus corroborating previous
results showing that these cells may support TTV replication and/or persistence.
TT virus (TTV) is a recently described single-stranded DNA
virus of humans that shares considerable similarities with the
chicken anemia virus and other circoviruses of animals. Unlike
related viruses, TTV is characterized by a great genetic heter-
ogeneity and by a seemingly absolute lack of pathological ef-
fects for infected hosts. In fact, the original suggestion that
TTV might be responsible for at least some of the acute and
chronic forms of hepatitis that still remain cryptogenetic has
not been substantiated, and no other illness has yet been as-
sociated with certainty to the virus.
Although sensitive PCR assays have documented that TTV
produces long-lasting, possibly permanent infections in most
infected individuals and that plasma viremia is highly prevalent
in the general population throughout the world (1, 6, 8, 24, 31),
the natural history of TTV infection is still poorly understood.
Suggestions that the liver is a major site of replication (26)
have been questioned (9). On the other hand, the observation
that TTV is consistently found associated with extensively
washed peripheral blood mononuclear cells (PBMC) and
grows in cultured phytohemagglutinin-stimulated PBMC (13,
25, 27) is evidence for a more or less pronounced tropism for
lymphoid tissues.
Analysis of viral dynamics following initiation of antiviral
treatments has been helpful in resolving the natural history of
several persistent viruses, including human immunodeficiency
virus type 1 (HIV-1), hepatitis B virus, and hepatitis C virus
(HCV), and has provided useful clues for optimizing therapeu-
tic protocols (17, 22, 30). HCV is an important cause of chronic
liver damage and may lead to decompensated cirrhosis and
hepatocellular carcinoma, usually after an indolent course of
two or more decades. Prolonged administration of alpha inter-
feron (IFN-), alone or in combination with the synthetic
purine analogue ribavirin, remains crucial in efforts to reduce
the detrimental effects of HCV infection on the liver, even
though sustained virological responses are observed in only a
minority of treated patients (5, 11). In an attempt to shed light
on TTV-host interactions, we have investigated the dynamics
of TTV, and for comparison HCV, in patients chronically
infected with both viruses during the early stages of IFN treat-
ment. The results have shown that, as in the case of other
chronic plasma viremia-inducing viruses previously investi-
gated, persistent TTV viremia implies an extremely active on-
going virus replication.
MATERIALS AND METHODS
Patients and samples. The study group consisted of 25 randomly selected
patients (19 males and 6 females; mean age, 44 10 years; range, 26 to 63 years)
with chronic dual HCV and TTV infection. All patients were free from hepatitis
B virus and human HIV-1 and -2 infections and, prior to initiation of the study,
had received no antiviral or immunosuppressive treatments. The patients were
subcutaneously administered 3 (7 subjects) or 6 (18 subjects) international
megaunits of recombinant IFN-2 (rIFN-2 [Intron A]; Schering-Plough, Mad-
ison, N.J.) three (15 subjects) or seven (10 subjects) times per week throughout
the 3 months of follow-up, and 4 also received 1,000 mg of ribavirin per day after
the last month. Because the study was not designed to evaluate the effects of
different forms of therapy and no differences were noted in the limited subgroups
studied, the patients were pooled into a single group. After informed consent,
patients were bled with EDTA tubes at day 0, 1, 2, 3, 7, 14, 30, and 90 of therapy.
Total PBMC were obtained by standard Ficoll-Hypaque density-gradient cen-
trifugation (Lympho separation medium; ICN Biomedicals, Aurora, Ohio),
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washed with abundant phosphate-buffered saline, and treated to achieve maxi-
mum elimination of adsorbed extracellular virus as previously described (13).
Plasma and PBMC samples were immediately stored at 80°C and kept frozen
until use. Viral nucleic acids were extracted by the method included in the
Amplicor Monitor version 2.0 (Roche Diagnostic Systems, Basel, Switzerland)
for HCV and QIAamp DNA Blood Mini kit (QIAgen, Chatsworth, Calif.) for
TTV. Four doubly infected patients, who had agreed to be left untreated and to
be bled monthly, were used to measure the extent of spontaneous viremia
fluctuations in the absence of antiviral treatments.
Viral load assays. TTV DNA quantification was carried out with a TaqMan
real-time PCR targeted to a segment of the untranslated region (UTR) of the
viral genome highly conserved among the ones deposited in gene banks at the
time of writing: forward primer 5-GTGCCGIAGGTGAGTTTA-3, position
177 to 194; reverse primer 5-AGCCCGGCCAGTCC-3, position 226 to 239;
probe 5-TCAAGGGGCAATTCGGGCT-3, position 205 to 223. The proce-
dures used for copy number quantification and evaluation of intra- and interassay
accuracy and reproducibility have been previously described (13, 31). The lower
limits of sensitivity were 1.0  103 and 1.0  102 TTV DNA copies per ml of
plasma or per g of total PBMC DNA, respectively. All samples from each
patient were assayed simultaneously in triplicate, and at least two independent
DNA extractions for each sample were examined. Samples positive in only one
replicate and/or with a coefficient of variation of 50% or greater were reextracted
and tested again in triplicate. Levels of HCV RNA in plasma were measured with
the Monitor 2.0 Roche assay with a lower limit of sensitivity of 1.0  103 copies
per ml.
Data analysis. Viral load data in the first week of treatment were analyzed by
using the model developed by Neumann et al. (17) to investigate the dynamics of
HCV infection in IFN-treated patients. In this analysis, we obtained least-square
estimates of the parameters t0, c and ε by fitting the equation V(t)  V0 {1  ε
 ε exp [c(t  t0)]} to the observed data. Here, V(t) is the viral load predicted
t days after initiation of therapy, ε is the efficacy of therapy at reducing virus
release from infected cells, c is the virion clearance rate, and exp represents the
exponential function. The model assumes that viral decay begins at a certain
time, t0, after the start of therapy, at a viral load V0. In order to keep the number
of parameters estimated from data at a minimum, we used the observed pre-
treatment viral load values for V0 in the equation presented above. Standard
errors of parameter estimates were obtained by the numerical resampling
method known as jackknifing (33). Virion half-life (t1/2) was obtained by the
equation ln(2)/c. Daily production of plasma virions (P) was calculated from cV0,
multiplied by the extracellular body fluid volume, which was arbitrarily set at
3.0  103 ml.
TTV genotyping. TTV genotype was determined by sequencing a 222-bp seg-
ment of open reading frame 1 (ORF1) as previously described (12) and, for
selected isolates, also a 204-bp segment of UTR according to Leary et al. (10).
Cycle sequencing was carried out with an automatic DNA sequencer (ABI model
373; PE Biosystems, Foster City, Calif.).
RESULTS
IFN-induced changes in plasma TTV viremia. Twenty-five
previously untreated patients doubly infected with TTV and
HCV were monitored for levels of the two viruses in plasma at
selected time points during the first 3 months of IFN therapy.
Overall data are shown in Table 1. At baseline, TTV values
ranged between 4.9 and 9.3 log10 DNA copies per ml of plasma
with a mean of 6.7 log10, confirming that plasma TTV loads
may vary extensively in individual patients, but tend to be
relatively high (31). At days 1 and 2 of therapy, two patients
showed a marginal reduction of plasma TTV levels, but the
others had either unchanged or slightly increased values rela-
tive to baseline. Thus, the first significant decline of mean
plasma TTV load occurred at day 3. Subsequently, increasing
numbers of patients showed levels of viral DNA in plasma
below detection sensitivity (3 log10 copies/ml), and up to day
30, the mean loads became progressively lower. At day 90, the
mean TTV load was slightly increased relative to that at day 30,
although the increase did not reach statistical significance.
Table 1 also shows that in the same patients, baseline levels
and responses to treatment of HCV were in line with published
data (3, 12, 19). A substantial decline in mean HCV viremia
was clearly evident at day 1 of treatment, when one patient was
already below the assay sensitivity limit (3 log10 copies/ml).
Subsequently, HCV viremia declined at a lower rate up to day
90, when the maximum proportion of patients who had cleared
the virus to an undetectable level (67%) was also observed. In
accord with previous findings (4, 18), in four untreated pa-
tients, monthly measurement of TTV and HCV levels in
plasma showed essentially stable values, with fluctuations of no
more than 0.6 and 0.5 log10 copies/ml, respectively (data not
shown).
Figure 1 shows the sequential modifications of plasma TTV
levels of the patients for whom a minimum of six sequential
samplings were available. One subject showed a maximum
decline of viremia of approximately 1 log10 copy/ml throughout
the observation period. The other 13 patients in this group
responded favorably to treatment, as demonstrated by viremia
levels under the detection limit at one or more sampling
points. It is noteworthy that only in three patients was the
beneficial effect of IFN evident from the first week of treat-
ment. It is also important to note that, in spite of continued
treatment, three responders had a relapse of TTV viremia
during the observation period. It should also be noted that, at
least in this limited group, negativity or positivity of TTV
TABLE 1. TTV and HCV detection and loads in the plasma of 25 doubly infected patients at selected times of IFN treatment
Day of
treatment
TTV HCV
No. positive/tested
(%)a
Loadb No. positive/tested
(%)a
Loadb
Mean  SE Rangec Mean  SE Rangec
0 25/25 (100) 6.7  0.2 4.9–9.3 25/25 (100) 6.0  0.2 4.7–7.4
1 25/25 (100) 6.7  0.2 4.9–10.3 22/23 (96) 5.2  0.2 3.4–6.3
2 18/18 (100) 6.8  0.2 5.6–9.4 12/15 (80) 5.0  0.3 3.7–6.6
3 12/12 (100) 5.9  0.3* 3.1–7.1 15/17 (88) 5.2  0.2** 4.9–6.7
7 13/14 (93) 5.5  0.3** 3.3–7.1 14/16 (87) 5.1  0.3*** 4.8–6.6
14 14/19 (74) 5.4  0.4** 5.2–8.6 17/20 (85) 4.5  0.2*** 3.3–6.7
30 6/14 (43) 3.8  0.3*** 3.6–7.0 10/18 (55) 4.3  0.3*** 5.3–6.2
90 7/17 (41) 4.1  0.4*** 3.5–7.6 6/18 (33) 4.2  0.4*** 5.3–7.1
a Not all samples were available for all patients at all times.
b Log10 copies of viral genome per milliliter of plasma. Viral loads below the detection assay sensitivity were arbitrarily scored as 3 log10 for calculation. *, **, ***,
significantly different from day 0 at P 	 0.05, P 	 0.01, and P 	 0.001, respectively (Student’s t test).
c Positive patients only.
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viremia at 90 days appeared essentially unrelated to virus ge-
notype and baseline viremia levels (Fig. 1).
Consistent with previous findings (3, 11, 17), the changes of
HCV plasma loads produced by IFN treatment were also var-
ied. After a prompt viremia reduction of variable extent and
duration observed in virtually all patients, HCV loads contin-
ued to decline in some individuals, remained essentially stable
in others, and rebounded to values equal to or greater than
pretreatment ones in still others (Fig. 1). The data were used
to calculate whether a correlation existed between baseline or
intratreatment levels of TTV and HCV in plasma. At no time,
were loads and responses to IFN treatment of the two viruses
found to correlate.
IFN-induced changes in PBMC-associated TTV. TTV has
previously been shown to circulate in blood closely associated
with PBMC as well as free virions (13, 25, 28). In eight patients
of Fig. 1, we also determined the loads of TTV DNA found in
thoroughly washed sequential PBMC samples. Consistent with
previous findings (13, 27), all baseline samples tested TTV
positive at copy numbers that varied widely in individual pa-
tients (Table 2). Following initiation of IFN treatment, PBMC-
associated TTV levels underwent a decline that was similar in
extent and kinetics to what was found for the corresponding
plasma samples at all times tested, except, possibly, it started a
little earlier, as suggested by the slightly reduced mean load
detected at day 2. In fact, viral loads in plasma and PBMC were
moderately to highly correlated in individual patients (r  0.31
FIG. 1. Effects of 3 months of IFN therapy on plasma loads of TTV (a and b) and HCV (c and d) in 14 doubly infected patients for whom a
minimum of six samplings were available. a and c, patients with baseline TTV load lower than the median; b and d, patients with baseline TTV
load higher than the median. Individual patients are color coded (solid symbols, patients infected with subtype 1 TTV; open symbols, patients
infected with other TTV genotypes). The horizontal broken line represents the lower limit of detection sensitivity.
TABLE 2. TTV detection and loads in the PBMC and plasma at
selected times of IFN treatment
Day of
treatment
No. of
patients
testeda
TTV DNA
PBMC Plasma
No. of
patients
positive
Log10 copies/g
of total DNA
(mean  SE)b
No. of
patients
positive
Log10 copies/ml
(mean  SE)b
0 8 8 5.8  0.5 8 6.2  0.4
1 8 8 5.9  0.6 8 6.1  0.3
2 8 8 5.3  0.6 8 6.5  0.2
3 5 5 4.9  0.6* 5 5.2  0.5*
7 8 8 5.2  0.6 8 5.3  0.4*
30 7 7 4.1  0.5* 5 4.2  0.6**
90 7 5 3.6  0.6** 3 4.1  0.6**
a Not all samples were available for all patients at all times.
b TTV loads below detection sensitivity were arbitrarily scored as 2 and 3 log10
copies/g of total DNA or per ml of plasma, respectively. * and **, significantly
different from day 0 at P 	 0.05 and P 	 0.01, respectively (Student’s t test).
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at baseline and r  0.87 at day 2). It should be noted, however,
that at late sampling points, some PBMC samples tested TTV
positive (in one case at 5.11 log10 per g of extracted DNA) in
spite of the fact that the corresponding plasma samples were
under the level of detection sensitivity (Table 2). This is in line
with findings showing that PBMC are not merely contaminated
by virus in plasma, but likely represent a site of active TTV
replication (13).
Dynamics of TTV. In chronically infected individuals, TTV
viremia fluctuates very little over periods of weeks or months
(described above), indicative of the existence of a quasi-steady-
state virus-host equilibrium resulting from balanced virus pro-
duction and elimination. We hence assumed that, prior to
treatment, the viral loads in the study patients were at steady
state and exploited the declines of TTV plasma viremia
brought about by IFN to look into the dynamics of chronic
TTV infection. Plasma viremia data from day 0 to day 7 of all
25 study patients were analyzed with a previously developed
mathematical model (17). By using nonlinear regression anal-
ysis, we estimated the overall values for delay of response to
IFN (t0), efficacy of the drug (ε), and virion clearance rate (c)
by fitting the model equation to mean viral loads. Figure 2a
and Table 3 show that TTV elimination from plasma started
after day 2 and was maximum between days 2 and 3, while
mean IFN effectiveness was 0.94. On the other hand, the clear-
ance rate of TTV from plasma was 2.5 days1, and the t1/2 of
TTV in plasma, calculated with such a value, was 0.27 days,
with large standard error values reflecting the wide variability
in response to treatment exhibited by individual patients. As-
suming that the rate of natural TTV clearance from the circu-
lation did not vary as a result of IFN treatment, this implies
that, on average, 94% of the TTV virions found in plasma of
chronically infected subjects turn over daily and that the min-
imum number of cell-free TTV particles cleared and replen-
ished daily to keep plasma viremia levels steady is 3.8  1010.
However, in view of the fact that most plasma TTV is com-
plexed with antibodies (20), it is possible that its clearance rate
is significantly affected by IFN treatment. Thus, calculated
values should be considered as approximate. As depicted in
Fig. 2b, the best-fit elimination curve of PBMC-associated
TTV was identical in shape to that of TTV in plasma, except
that the phase of the maximum elimination rate started some-
what earlier (t0  1.85 0.014 versus 2.07 0.012; P	 0.001).
In accord with previous findings (17), the same patients
showed a clearly biphasic elimination curve of plasma HCV,
with a very steep slope from day 0 to 1, followed by a phase of
slow or no decline (Fig. 2a). Calculated parameters for HCV
dynamics (Table 3) compared well with previously published
data (17, 34): in particular, t1/2 was 0.14 days, corresponding to
over 98% virions renewed per day and at least 2.7  1010
virions produced and cleared daily.
DISCUSSION
The present observation that in the early stages of IFN
treatment for hepatitis C most patients exhibited a marked
decline of concomitant TTV viremia confirms earlier reports
that TTV infection responds favorably to IFN treatment (2,
21). However, in spite of continued treatment, some initial
responders showed a TTV relapse before the end of the
3-month study period, suggesting that at least in some subjects,
this beneficial effect can be very short-lived. A previous report
that hepatitis C patients examined after 6 or more months of
IFN therapy had levels of TTV essentially unchanged relative
to pretreatment values (12) points to the same conclusion. The
observed lack of correlation between the responses of TTV
and HCV to therapy suggests that the factors that control the
responsiveness to IFN of the two viral infections are at least
partly independent. The parameters generally used as predic-
tors of HCV responsiveness to IFN therapy include virus ge-
FIG. 2. Mean TTV loads and best fit of the model with plasma of
all 25 patients in Table 1 (a) and in the PBMC and plasma of the 8
patients in Table 2 (b). For comparison, panel a also shows the cor-
responding curve for HCV. Bars represent 95% confidence limits of
the mean.
TABLE 3. TTV and HCV dynamics in doubly infected patients treated with IFN
Virus Effectiveness of drug ε(mean  SE)
Viral parameter (mean  SE)
Delay of drug response
(t0 [days])
Clearance rate
(c [days1])
Virion half-life
(t1/2 [days])a
Minimal input and
clearance of plasma
virions/day (1010)b
TTV 0.94  0.002 2.07  0.004 2.5  3.1 0.27  0.31 3.8  0.6
HCV 0.85  0.002 	1 5.0  4.1 0.14  0.03 2.7  0.4
a Calculated by the equation t1/2  ln (2)/c.
b Calculated by the equation P  cV0, assuming that plasma and extracellular fluids were 3.0  103 ml in total and in equilibrium. In this equation P represents daily
production of virions in plasma.
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notype, viral load, and quasispecies complexity (29). Here,
patients carrying genotype 1 or non-genotype 1 TTV or having
different pretreatment TTV loads showed no differences in
their ability to clear TTV in response to IFN, but further
studies involving larger series of patients will be needed to
draw conclusions on this matter. Being targeted to a highly
conserved domain of the viral UTR, the real-time PCR we
used to measure TTV loads detects a wide range of diverse
TTV genomes, some of which have recently been proposed to
represent distinct viral species (16, 32). Thus, it is most likely
that among the large variety of viral genomes currently labeled
as TTV, there are definite subtypes or species with different
IFN sensitivities.
Undoubtedly, the most interesting information that emerged
from this study is the estimate of the kinetics of chronic TTV
viremia we obtained by analyzing the observed IFN-induced
changes of TTV load with a mathematical model that has
provided valuable insights on other chronic viral infections (17,
30). The analysis showed that TTV sustains very active chronic
infections, with over 90% of the virions in plasma cleared and
replenished on a daily basis and a minimum of approximately
3.8  1010 virions generated per day. Thus, in this respect,
TTV resembles the other viruses that produce chronic plasma
viremia in humans, namely HCV, HIV-1, and hepatitis B virus,
which have previously been shown to sustain highly dynamic
chronic infections (5, 22, 30). For example, the estimated num-
bers of HCV virions produced daily by chronically infected
patients have ranged between 109 and 1012 in different studies
(17, 34) and averaged 2.7  1010 in our patients.
Different from the other known viruses of humans that pro-
duce chronic plasma viremia, TTV lacks an external cell-de-
rived envelope that might permit the egress of virions from
intact cells with little or no cytopathology. Thus, unless virus
yield per infected cell is unusually high, the copious production
of virions that occurs during chronic TTV infection should be
expected to produce substantial cytolysis. Because no patho-
logical effects have unequivocally been ascribed to TTV, this in
turn might imply that it replicates in cell types that tolerate
extensive destruction with no clinical consequences, possibly
due to the existence of large reservoirs and/or regenerative
potential. Although the cells supporting TTV replication in
infected hosts are still poorly defined, current evidence points
to liver (26) and lymphoid tissues (9, 13), two districts which
would correspond to such a requisite. Resembling what was
previously observed with HIV-1 following antiretroviral che-
motherapy (7), the levels of PMBC-associated and plasma
TTV declined at about the same rate as a result of IFN ther-
apy. However, low levels of TTV were occasionally detected in
the PBMC of patients who had cleared the virus from plasma,
thus corroborating results showing that lymphoid tissues may
support TTV replication (13). Interestingly, while in analogy
with previous reports (3, 17), the decline of HCV viremia was
already clearly evident within 1 day from initiation of IFN
treatment, that of TTV became detectable only at day 3. Be-
cause it seems unlikely that this lag reflects differences in the
efficacy of IFN at inhibiting virus replication in different cell
types or body sites, it is plausible that TTV release into the
circulation continues for some time after initiation of IFN
administration, due to continuing lysis of cells that have al-
ready progressed through virus replication to a phase no longer
susceptible to IFN. Alternatively, the bulk of TTV replication
might occur in districts in which exchanges with blood are
relatively slow, hence representing a sort of virus reservoir.
According to a recent study (14), that the decline of plasma
HIV-1 loads induced by highly active antiretroviral therapy is
slower to start than that the decrease in plasma HCV loads
induced by IFN should be attributed to the fact that most
HIV-1 is produced in lymphoid tissues, whereas most HCV
replicates in the liver and is therefore virtually released directly
into blood. The latter explanation would also imply that the
estimate presented above for total daily TTV production is
indeed minimal and should be considerably increased.
When incubated at 37°C in vitro, TTV detectability exhib-
ited an estimated half-life of over 5 days versus approximately
7 h in vivo (data not shown). This confirms that TTV is a very
stable virus, as is predictable from inferred structural proper-
ties (15, 23) and indicated by a previous study (13), and also
suggests that powerful mechanisms are operative in vivo that
continuously and very effectively clear the virus from blood.
Possible mechanisms of TTV clearance from the circulation
include virus adsorption to susceptible cells and uptake by
phagocytic cells. Although immune responses to TTV are just
beginning to be unveiled, current data (20) and our own un-
published results show that a variable but generally large por-
tion of the cell-free virus in plasma of persistently infected
individuals is in the form of immune complexes. It is hence
feasible that antiviral antibodies play an important role in
clearing the virus from the circulation, by opsonizing the viri-
ons for phagocytic cells or other means. Further studies should
clarify whether the abundant immune-complexed TTV circu-
lating in chronically infected individuals is still capable of ini-
tiating cell infection, thus possibly shedding light on why anti-
bodies are incapable of eradicating a putatively cytocidal virus
that circulates so extensively in plasma.
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